Yahoo Finance Results
- Motley Fool via Yahoo FinanceMay 13 10:31 AM
All three of these apply to Pfizer (NYSE: PFE), but they also all apply to Merck (NYSE: MRK). Although quarterly results present only a snapshot of a company's performance, it's still ...
- InvestorPlace via Yahoo Finance2 days ago
- Zacks via Yahoo Finance2 days ago
- Bloomberg2 days ago
- Markit via Yahoo FinanceMay 09 12:00 PM
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks via Yahoo FinanceMay 11 13:25 PM
Both Merck & Co., Inc. MRK and Pfizer, Inc. PFE reported upbeat first-quarter results on May 1. Merckhas a Zacks Rank #2 (Buy), while Pfizer possesses a Zacks Rank ...
- Reuters via Yahoo FinanceMay 15 18:07 PM
Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up ...
- Zacks via Yahoo FinanceMay 14 13:38 PM
President Donald Trump on Friday unveiled his plans of lowering drug prices, in keeping with promises he made in the run-up to the Presidential elections. Pharmaceutical companies and the broader ...
- Bloomberg via Yahoo FinanceMay 08 17:51 PM
Adults and children with severe allergies are experiencing problems finding EpiPens after issues with manufacturing of the lifesaving devices, according to patients and pharmacists. More than ...
- InvestorPlace via Yahoo FinanceMay 08 19:11 PM
The former is recession proof, while the latter always seems able to find a market by constantly reinventing its drug portfolio, making them a couple of the best income-producing assets the ...
- Zacks via Yahoo FinanceMay 09 13:01 PM
Momenta Pharmaceuticals Inc. MNTA reported a loss per share of 63 cents in the quarter, wider than the year-ago loss of 46 cents. Momenta’s top-line comprises product revenues of $3.5 ...
- Reuters via Yahoo FinanceMay 09 17:39 PM
EpiPen shortages, on Tuesday said it notified the FDA a few months ago of supply issues due to delays at manufacturing partner Pfizer Inc.
- Zacks via Yahoo FinanceMay 07 12:30 PM
The first-quarter earnings season has been relatively strong. While positive revisions were seen ahead of the start of the Q1 earnings season, the estimate revision trend for the second quarter has been rather underwhelming.
- related to PFIZER INC